EXELIXIS INCDRNEXELIXIS INCDRNEXELIXIS INCDRN

EXELIXIS INCDRN

No trades
See on Supercharts

Key stats

Market capitalization
‪35.82 B‬BRL
Dividend yield (indicated)
Price to earnings Ratio (TTM)
Basic EPS (TTM)
Net income (FY)
Revenue (FY)
Shares float
Beta (1Y)
−0.08

About Exelixis, Inc.

CEO
Michael M. Morrissey
Headquarters
Alameda
Founded
1994
ISIN
BRE2XEBDR001
FIGI
BBG014XJH5R3
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where E2XE34 is featured.